| Type | Title | Date Released | |
|---|---|---|---|
6-K | MindWalk Announces Multi-Year Agreement with Teva Australia for ReefIQ™ and LensAI™ Deployment | ||
6-K/A | Form 6-K/A | ||
6-K | Notice of MindWalk Holdings Corp. Annual General Meeting of Shareholders | ||
6-K | MindWalk Holdings Announces Departure of Chief Business Officer Thomas Lynch | ||
6-K | MindWalk Screens 890,634 Antibody Sequences for Immune Risk in Under Five Hours Using LensAI™ on AWS and AMD | ||
6-K | MindWalk Holdings Strengthens Boston Leadership as Pipeline Advances Toward Preclinical Efficacy Studies | ||
6-K | MindWalk Outlines ReefIQ™ as the Biological Context Layer for Life Sciences AI | ||
6-K | MindWalk Appoints Kim Remizowski to Board of Directors as Independent Director | ||
6-K | ImmunoPrecise Antibodies Ltd. Files Form 6-K Regarding Notice of Meeting and Record Date | ||
6-K | MindWalk Brings OpenFold3 into Production in Minutes with AMD Inference Microservices on Vultr Kubernetes Engine | ||
6-K | MindWalk Reports 21% Revenue Growth and Gross Margin Expansion to 59% in Fiscal First Quarter 2027 | ||
6-K | MindWalk Holdings Corp. Reports Management Discussion and Analysis for the Three Months Ended July 31, 2026 |
